Welcome to our dedicated page for QT Imaging Holdings SEC filings (Ticker: QTIH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QT Imaging Holdings, Inc. (QTIH) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and related exhibits. QT Imaging is a medical device company in the healthcare sector that develops and commercializes body imaging systems using low frequency sound waves, and its filings offer detailed insight into its capital structure, financing arrangements, and operational progress.
Investors can review Form 8-K current reports where QT Imaging discloses material events such as private placement (PIPE) financings, warrant repurchases, amendments to credit agreements, and the implementation of a 3:1 reverse stock split of its common stock. Certain 8-K filings also furnish unaudited pro forma condensed consolidated financial statements, which show how transactions like the September 2025 private placement and subsequent debt repayments affect the company’s balance sheet and statements of operations.
The company has filed a Form S-1 registration statement and an amended Form S-1/A, which contain information about its securities, historical financial statements, and various equity and debt instruments, including warrants, convertible notes, bridge loans, and earnout arrangements. These documents, together with other periodic and transactional filings, outline QT Imaging’s status as an emerging growth company and describe key elements of its financing history and customer concentration.
On Stock Titan, these filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries help explain the significance of complex disclosures, highlighting items such as changes to rights of security holders, reverse stock split mechanics, private placement terms, and pro forma adjustments. Users can quickly locate quarterly and annual financial information within registration statements, track capital markets actions, and examine how QT Imaging reports on its imaging business, cloud platform development, and related risks in its official SEC documents.
QT Imaging Holdings, Inc. updated compensation for its top executives. The Board increased Chief Executive Officer Dr. Raluca Dinu’s annual base salary from $550,000 to $605,000, effective March 20, 2026, and approved a cash bonus of $231,993 for her.
Chief Financial Officer Jay Jennings received a cash bonus of $40,576. The Board also granted Dr. Dinu a total of 519,500 restricted stock units (RSUs), split into grants of 3,500, 16,000 and 500,000 RSUs, vesting in scheduled installments from May 15, 2026 through February 15, 2030, contingent on continued service.
Mr. Jennings received a grant of 2,800 RSUs, with 933 RSUs vesting on May 15, 2027 and the remaining 1,867 RSUs vesting in eight quarterly installments through May 15, 2029, also subject to his continued service with the company.
QT Imaging Holdings, Inc. files its annual report describing a breast imaging business built around its QT Breast Scanner, a 3D ultrasound tomography system that avoids ionizing radiation and breast compression. The device received initial FDA 510(k) clearance in June 2017, an additional quantitative breast density clearance in August 2022, and a further clearance on March 10, 2026 for an enhanced configuration that improves imaging of posterior breast tissue near the chest wall.
The company outlines a strategy to evolve from a hardware maker into a precision imaging platform by adding a cloud SaaS infrastructure and future AI modules for quantitative biomarkers and diagnostic decision support. It targets the breast imaging market, which the report cites at about $6.04 billion globally in 2025, and references broader medical imaging and cancer screening markets. Commercially, QT Imaging has an exclusive U.S. distribution agreement with NXC Imaging, tied to minimum order quantities, and exclusive distribution deals with Gulf Medical Co. in Saudi Arabia and Al Naghi Medical Co. in the UAE. The Al Naghi agreement includes minimum orders totaling 43 scanners from 2026 through 2028, representing more than $24 million in revenue commitments, subject to performance and supply conditions.
Taylor Ross reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings director Taylor Ross received an equity grant of 3,500 shares of Common Stock on March 20, 2026, at no cash cost. Following this award, Ross directly holds 60,578 shares. The grant is in the form of Restricted Stock Units that vest in four equal installments on May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, subject to continued service. All units vest immediately if there is a Change of Control under the company’s 2024 Equity Incentive Plan.
GREENE JAMES S reported acquisition or exercise transactions in this Form 4 filing.
QT IMAGING HOLDINGS, INC. director James S. Greene reported an equity award of 3,500 shares of Common Stock, bringing his direct holdings to 3,500 shares. The award is structured as Restricted Stock Units that vest 25% on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, subject to his continued service. All RSUs will fully vest immediately if there is a Change of Control as defined in the company’s 2024 Equity Incentive Plan.
Jennings Jay Walter reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Financial Officer Jay Walter Jennings received a grant of 2,800 shares of common stock on March 20, 2026 as a stock award. The grant price per share was $0.00, and his direct holdings after the award total 2,800 shares.
According to the vesting schedule, one-third of the related restricted stock units vest on May 15, 2027, with the remaining two-thirds vesting in eight equal quarterly installments on each subsequent August 15, November 15, February 15, and May 15, so that the grant is fully vested on May 15, 2029. All such units will immediately vest if there is a Change of Control as defined in the company’s 2024 Equity Incentive Plan.
KLOCK JOHN C JR reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that director and ten percent owner John C. Klock Jr. received a grant of 3,500 shares of Common Stock as a restricted stock unit award at a stated price of $0.00 per share, increasing his direct holdings to 3,500 shares.
According to the award terms, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, as long as he continues serving the company. All units will vest immediately if there is a Change of Control under the company’s 2024 Equity Incentive Plan.
Dinu Raluca reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Executive Officer Raluca Dinu received equity awards of common stock as compensation. On March 20, 2026, she was granted 3,500, 500,000, and 16,000 shares of common stock at a price of $0.00 per share under the company’s equity plan.
After these awards, the filing shows she directly owns 908,845 common shares. Footnotes explain these are restricted stock units with vesting schedules running from May 15, 2026 through dates as late as February 15, 2030 or May 15, 2029, with full acceleration upon a qualifying Change of Control.
Katz Avi S reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. chairman Avi S. Katz received a grant of 3,500 shares of common stock on March 20, 2026 as a stock award, at a stated price of $0.00 per share. Following this grant, he directly holds 416,952 common shares.
The award is structured as restricted stock units. Subject to his continued service, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately if the company undergoes a Change of Control under its 2024 Equity Incentive Plan.
QT Imaging Holdings, Inc. released an investor presentation highlighting rapid commercial growth for its breast imaging platform and updated financials. Revenue reached $18.9 million in 2025, up from $4.9 million in 2024, driven by shipment of 40 QT Breast Acoustic CT scanners under distribution agreements.
Q4 2025 revenue was $8.3 million, an 877% year-over-year increase, with 38% gross margin and a net loss of $1.4 million. Adjusted EBITDA improved to $(0.4) million from $(1.9) million a year earlier. The company ended 2025 with $10.5 million in cash after an oversubscribed $18.2 million private placement and new debt financing, and it expects approximately $39 million of revenue in 2026, including initial SaaS cloud platform contributions.
QT Imaging Holdings, Inc. reported preliminary unaudited results showing record revenue of $8.3 million in Q4 2025 and $18.9 million for full-year 2025, exceeding its $18 million outlook. Q4 revenue rose 877% year over year and 97% sequentially, driven by shipment of 17 Breast Acoustic CT™ scanners.
For 2025, revenue grew 288% versus 2024, with 40 scanners shipped. Gross margin was 45% for the year and 38% in Q4. Despite this growth, the company recorded a 2025 net loss of $21.1 million, influenced by $8.8 million of other expense tied to term loan issuance, note extinguishments and fair value changes.
Non-GAAP Adjusted EBITDA improved to $(3.5) million from $(7.4) million in 2024, while net cash used in operating activities narrowed to $9.0 million. Cash, restricted cash and equivalents reached $10.5 million at year-end 2025 after an $18.2 million private placement and new debt financings. The company relisted on Nasdaq and is pivoting from pure hardware to a SaaS and biomarker-driven imaging platform, and it projects 2026 revenue of about $39 million, including initial SaaS Cloud Platform contributions.